JP2014518893A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518893A5
JP2014518893A5 JP2014513784A JP2014513784A JP2014518893A5 JP 2014518893 A5 JP2014518893 A5 JP 2014518893A5 JP 2014513784 A JP2014513784 A JP 2014513784A JP 2014513784 A JP2014513784 A JP 2014513784A JP 2014518893 A5 JP2014518893 A5 JP 2014518893A5
Authority
JP
Japan
Prior art keywords
nanoparticles
agent
cancer
chemoattractant
cytotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014513784A
Other languages
English (en)
Other versions
JP6062426B2 (ja
JP2014518893A (ja
JP2014518893A6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/040687 external-priority patent/WO2012167230A1/en
Publication of JP2014518893A publication Critical patent/JP2014518893A/ja
Publication of JP2014518893A6 publication Critical patent/JP2014518893A6/ja
Publication of JP2014518893A5 publication Critical patent/JP2014518893A5/ja
Application granted granted Critical
Publication of JP6062426B2 publication Critical patent/JP6062426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

[本発明1001]
プロセシングされた腫瘍抗原をインサイチューにおいて産生するための生検不要の方法であって、癌と診断された対象に、癌細胞の化学誘因物質を含む多孔性三次元足場を投与する工程、該足場を、循環性癌細胞を蓄積するのに十分な期間、インサイチューにおいて維持して、癌細胞含有足場を得る工程、および、該細胞含有足場を細胞毒性因子または細胞溶解性因子に接触させて、プロセシングされた腫瘍抗原を産生する工程を含む、方法。
[本発明1002]
前記細胞毒性因子が、前記細胞含有足場への外部からの熱、超音波、レーザー照射、またはγ線照射の適用を含む、本発明1001の方法。
[本発明1003]
前記レーザー照射が紫外線または近赤外線のレーザー照射を含む、本発明1002の方法。
[本発明1004]
前記足場が高体温誘発組成物をさらに含む、本発明1001の方法。
[本発明1005]
前記高体温誘発組成物が磁性ナノ粒子または近赤外線(NIR)吸収ナノ粒子を含む、本発明1004の方法。
[本発明1006]
前記ナノ粒子が磁性であり、かつ、前記方法が、インサイチューにおいて局所的高体温を誘発するために磁性ナノ粒子を交番磁界に接触させる工程、それによって前記癌細胞を崩壊させる工程、および、プロセシングされた腫瘍抗原を産生する工程をさらに含む、本発明1005の方法。
[本発明1007]
前記NIRナノ粒子が、金ナノロッド、金ナノシェル、金ナノケージ、貴金属ナノ粒子、炭素ナノチューブ、炭素ナノ粒子、およびグラファイトナノ粒子からなる群より選択され、かつ、前記方法が、インサイチューにおいて局所的高体温を誘発するために該NIRナノ粒子をNIR照射に接触させる工程、それによって前記癌細胞を崩壊させる工程、および、プロセシングされた腫瘍抗原を産生する工程をさらに含む、本発明1005の方法。
[本発明1008]
前記癌細胞の化学誘因物質が、CCL-21、CCL-19、SDF-1、VEGF、およびIL-4からなる群より選択されるケモカインを含む、本発明1001の方法。
[本発明1009]
前記癌が循環性腫瘍細胞を特徴とする、本発明1001の方法。
[本発明1010]
前記対象が転移性癌状態または白血病と診断されている、本発明1001の方法。
[本発明1011]
多孔性ポリマー、癌細胞のための化学誘因物質、および細胞毒性誘発組成物を備える、腫瘍抗原プロセシング装置。
[本発明1012]
前記細胞毒性誘発組成物が高体温誘発粒子を含む、本発明1011の装置。
[本発明1013]
前記細胞毒性誘発組成物が金ナノ粒子または金ナノロッドを含む、本発明1011の装置。
[本発明1014]
免疫細胞補充組成物をさらに備える、本発明1011の装置。
[本発明1015]
前記免疫細胞補充組成物が顆粒球マクロファージコロニー刺激因子を含む、本発明1014の装置。
[本発明1016]
前記化学誘因物質、前記細胞毒性誘発組成物、および前記免疫細胞補充組成物が前記多孔性ポリマー全体に散在する、本発明1014の装置。
[本発明1017]
前記多孔性ポリマーが、前記化学誘因物質および前記細胞毒性誘発組成物を含む第一の領域、ならびに、前記免疫細胞補充組成物を含む第二の領域を含む、本発明1014の装置。
[本発明1018]
前記第一の領域がコアとして構成され、かつ、前記第二の領域がシェルとして構成される、本発明1015の装置。
本発明のその他の特徴および利点は、それらの好ましい態様についての以下の記載および特許請求の範囲から明らかとなる。別途定義される場合を除いて、本明細書で用いられるすべての技術的および科学的用語は、本発明が属する技術分野の当業者によって一般的に理解されるものと同一の意味を持つ。以下に記載されるものと同等または等価の方法および材料は、本発明の実践または試験において用いることができるが、以下では適切な方法および材料について記載する。本明細書において言及されるすべての刊行物、特許出願、特許、Genbank/NCBIアクセッション番号、およびその他の参照は、参照により全体が組み入れられる。矛盾する場合は、定義を含めて本明細書が管理する。さらに、材料、方法および実施例は、説明のためのものであり、限定を意図するものではない。

Claims (18)

  1. 癌細胞の化学誘因物質を含む多孔性三次元足場を含む、癌と診断された対象においてプロセシングされた腫瘍抗原をインサイチュー産生するためのであって、該足場循環性癌細胞を蓄積するのに十分な期間、インサイチューにおいて維持され、癌細胞含有足場られ、該細胞含有足場細胞毒性因子または細胞溶解性因子に接触て、プロセシングされた腫瘍抗原を産生する、前記剤
  2. 前記細胞毒性因子が、前記細胞含有足場への外部からの熱、超音波、レーザー照射、またはγ線照射の適用を含む、請求項1記載の
  3. 前記レーザー照射が紫外線または近赤外線のレーザー照射を含む、請求項2記載の
  4. 前記足場が高体温誘発組成物をさらに含む、請求項1記載の
  5. 前記高体温誘発組成物が磁性ナノ粒子または近赤外線(NIR)吸収ナノ粒子を含む、請求項4記載の
  6. 前記ナノ粒子が磁性ナノ粒子であり、かつ、インサイチューにおいて局所的高体温を誘発するために磁性ナノ粒子を交番磁界に接触させる工程、それによって前記癌細胞を崩壊させる工程、および、プロセシングされた腫瘍抗原を産生する工程と組み合わせて使用される、請求項5記載の
  7. 前記NIRナノ粒子が、金ナノロッド、金ナノシェル、金ナノケージ、貴金属ナノ粒子、炭素ナノチューブ、炭素ナノ粒子、およびグラファイトナノ粒子からなる群より選択され、かつ、インサイチューにおいて局所的高体温を誘発するために該NIRナノ粒子をNIR照射に接触させる工程、それによって前記癌細胞を崩壊させる工程、および、プロセシングされた腫瘍抗原を産生する工程と組み合わせて使用される、請求項5記載の
  8. 前記癌細胞の化学誘因物質が、CCL-21、CCL-19、SDF-1、VEGF、およびIL-4からなる群より選択されるケモカインを含む、請求項1〜7のいずれか一項記載の
  9. 前記癌が循環性腫瘍細胞を特徴とする、請求項1〜8のいずれか一項記載の
  10. 前記対象が転移性癌状態または白血病と診断されている、請求項1〜9のいずれか一項記載の
  11. 多孔性ポリマー、癌細胞のための化学誘因物質、および細胞毒性誘発組成物を備える、腫瘍抗原プロセシング装置。
  12. 前記細胞毒性誘発組成物が高体温誘発粒子を含む、請求項11記載の装置。
  13. 前記細胞毒性誘発組成物が金ナノ粒子または金ナノロッドを含む、請求項11記載の装置。
  14. 免疫細胞補充組成物をさらに備える、請求項11記載の装置。
  15. 前記免疫細胞補充組成物が顆粒球マクロファージコロニー刺激因子を含む、請求項14記載の装置。
  16. 前記化学誘因物質、前記細胞毒性誘発組成物、および前記免疫細胞補充組成物が前記多孔性ポリマー全体に散在する、請求項14記載の装置。
  17. 前記多孔性ポリマーが、前記化学誘因物質および前記細胞毒性誘発組成物を含む第一の領域、ならびに、前記免疫細胞補充組成物を含む第二の領域を含む、請求項14記載の装置。
  18. 前記第一の領域がコアとして構成され、かつ、前記第二の領域がシェルとして構成される、請求項17記載の装置。
JP2014513784A 2011-06-03 2012-06-04 インサイチュー抗原生成癌ワクチン Active JP6062426B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161493398P 2011-06-03 2011-06-03
US61/493,398 2011-06-03
PCT/US2012/040687 WO2012167230A1 (en) 2011-06-03 2012-06-04 In situ antigen-generating cancer vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016241863A Division JP2017071638A (ja) 2011-06-03 2016-12-14 インサイチュー抗原生成癌ワクチン

Publications (4)

Publication Number Publication Date
JP2014518893A JP2014518893A (ja) 2014-08-07
JP2014518893A6 JP2014518893A6 (ja) 2014-11-20
JP2014518893A5 true JP2014518893A5 (ja) 2015-07-09
JP6062426B2 JP6062426B2 (ja) 2017-01-18

Family

ID=47259942

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014513784A Active JP6062426B2 (ja) 2011-06-03 2012-06-04 インサイチュー抗原生成癌ワクチン
JP2016241863A Pending JP2017071638A (ja) 2011-06-03 2016-12-14 インサイチュー抗原生成癌ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016241863A Pending JP2017071638A (ja) 2011-06-03 2016-12-14 インサイチュー抗原生成癌ワクチン

Country Status (6)

Country Link
US (2) US9486512B2 (ja)
EP (1) EP2714073B1 (ja)
JP (2) JP6062426B2 (ja)
AU (1) AU2012261848B2 (ja)
CA (1) CA2838125A1 (ja)
WO (1) WO2012167230A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2347774B1 (en) 2005-12-13 2017-07-26 The President and Fellows of Harvard College Scaffolds for cell transplantation
WO2009002401A2 (en) * 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
WO2011014871A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
EP2838515B1 (en) 2012-04-16 2019-11-20 President and Fellows of Harvard College Mesoporous silica compositions for modulating immune responses
JP6787789B2 (ja) 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
US10821208B2 (en) 2014-04-04 2020-11-03 President And Fellows Of Harvard College Click-crosslinked hydrogels and methods of use
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
US10143988B2 (en) 2015-05-08 2018-12-04 North Carolina State University Method for synthesizing non-spherical nanostructures
CN105169385B (zh) * 2015-07-13 2019-03-12 国家纳米科学中心 一种用于疫苗的非载体佐剂、其制备方法及应用
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
US10835604B2 (en) 2015-08-13 2020-11-17 Northeastern University Biomaterials for combined radiotherapy and immunotherapy of cancer
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
CN109069874A (zh) * 2016-01-07 2018-12-21 密歇根大学董事会 用于在体内捕获转移性乳腺癌细胞的植入式支架
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
CN105796510B (zh) * 2016-02-19 2019-05-31 泰山医学院 肿瘤靶向的药剂及其制备方法和应用
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
JP6914487B2 (ja) * 2016-11-24 2021-08-04 国立研究開発法人物質・材料研究機構 がん温熱治療用ナノ粒子と生体吸収性高分子との複合多孔質材料及びその製造方法
WO2018227205A1 (en) * 2017-06-09 2018-12-13 President And Fellows Of Harvard College Compositions for inducing an immune response
US11331019B2 (en) 2017-08-07 2022-05-17 The Research Foundation For The State University Of New York Nanoparticle sensor having a nanofibrous membrane scaffold
CN108743941B (zh) * 2018-05-08 2021-05-18 上海师范大学 巨噬细胞担载不同表面电荷的Au纳米棒及其制备方法和应用
US11344740B2 (en) 2019-02-07 2022-05-31 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
CN113692302A (zh) 2019-02-07 2021-11-23 V·K·沙玛 用交替极性磁场治疗癌细胞的系统及方法
US11027143B2 (en) 2020-02-06 2021-06-08 Vivek K. Sharma System and methods for treating cancer cells with alternating polarity magnetic fields
WO2021061837A1 (en) * 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
GB9206504D0 (en) 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges as wound implants
CA2178902A1 (en) 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
WO1997045533A1 (en) 1996-05-28 1997-12-04 The Regents Of The University Of Michigan Engineering oral tissues
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
DE69739085D1 (de) 1996-09-19 2008-12-18 Univ Michigan Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate
US5863551A (en) 1996-10-16 1999-01-26 Organogel Canada Ltee Implantable polymer hydrogel for therapeutic uses
GB2318577B (en) 1996-10-28 2000-02-02 Johnson & Johnson Medical Solvent dried polysaccharide sponges
GB2323282B (en) 1997-03-17 2001-03-07 Bristol Myers Squibb Co Improvements relating to hygiene and medical products
CA2285329A1 (en) 1997-03-31 1998-10-08 The Regents Of The University Of Michigan Open pore biodegradable matrices and process for making them
JP4132089B2 (ja) 1997-05-30 2008-08-13 オステオバイオロジックス,インコーポレイテッド 繊維強化多孔性生体分解性移植デバイス
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US7427602B1 (en) 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
FR2780730B1 (fr) 1998-07-01 2000-10-13 Corneal Ind Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique
EP1100529B2 (en) 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
JP2002527408A (ja) 1998-10-09 2002-08-27 ミシガン大学 ドラッグデリバリー用ヒドロゲル及び水溶性ポリマーキャリアー
AU2875700A (en) 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6541022B1 (en) 1999-03-19 2003-04-01 The Regents Of The University Of Michigan Mineral and cellular patterning on biomaterial surfaces
US6767928B1 (en) 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
WO2000056376A1 (en) 1999-03-25 2000-09-28 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
CA2364570A1 (en) 1999-04-09 2000-10-19 The Regents Of The University Of Michigan Preparing porous hydrogel products
AU782297B2 (en) 1999-06-30 2005-07-14 Ethicon Inc. Porous tissue scaffoldings for the repair or regeneration of tissue
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
AU6526100A (en) 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
AU1622801A (en) 1999-11-18 2001-05-30 Regents Of The University Of Michigan, The Sustained drug delivery from structural matrices
US6790840B1 (en) 1999-11-26 2004-09-14 The Regents Of The University Of Michigan Reversibly cross-linked hydrogels
US20020061587A1 (en) 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1311657A2 (en) 2000-08-21 2003-05-21 Rice University Tissue engineering scaffolds promoting matrix protein production
EP1315829B1 (en) 2000-09-09 2010-07-28 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6748954B2 (en) 2000-10-27 2004-06-15 The Regents Of The University Of Michigan Drug release from polymer matrices through mechanical stimulation
AU2002212739A1 (en) 2000-11-14 2002-05-27 Osteogenesis Co., Ltd. Compositions for forming bone or periodontium and injections for forming bone orperiodontium
CA2434320A1 (en) 2001-01-24 2002-08-01 Schering Corporation Chemokines as adjuvants of immune response
US7029697B2 (en) 2001-02-14 2006-04-18 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
JP4215512B2 (ja) 2001-02-26 2009-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非オリゴマー化タンデム蛍光性タンパク質
JP2002263981A (ja) 2001-03-14 2002-09-17 Murata Mach Ltd 板材吸着持ち上げ装置の吸着制御装置
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
US6656488B2 (en) 2001-04-11 2003-12-02 Ethicon Endo-Surgery, Inc. Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering
WO2002087627A1 (en) 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells
AU2002345691C1 (en) 2001-06-13 2008-07-24 Massachusetts Institute Of Technology In vivo bioreactors
US7297343B2 (en) 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
MXPA04006438A (es) 2001-12-31 2005-06-08 Ares Lab Llc Composiciones hemostaticas y metodos para el control de sangrado.
US7575759B2 (en) 2002-01-02 2009-08-18 The Regents Of The University Of Michigan Tissue engineering scaffolds
US6811777B2 (en) 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
EP1497424A1 (en) 2002-04-22 2005-01-19 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
AU2003234159A1 (en) 2002-04-22 2003-11-03 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
US20040242469A1 (en) 2002-05-13 2004-12-02 Lee Richard T. Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7332160B2 (en) 2002-07-12 2008-02-19 Boston Scientific Scimed, Inc. Medical device and method for tissue removal and repair
US20040136968A1 (en) 2002-09-27 2004-07-15 Verigen Ag Autologous cells on a support matrix for tissue repair
US20040063206A1 (en) 2002-09-30 2004-04-01 Rowley Jon A. Programmable scaffold and method for making and using the same
WO2004030706A2 (en) 2002-10-01 2004-04-15 Law Peter K Bioactive implants
US8940292B2 (en) 2003-01-28 2015-01-27 Wake Forest University Health Sciences Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
DK1620140T3 (da) 2003-05-05 2013-12-09 Univ Ben Gurion Injicerbare tværbundne polymere præparater samt deres anvendelse
EP1475434A1 (en) 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells
EP1641424A4 (en) 2003-07-09 2007-05-02 Vaxdesign Corp PROGRAMMED IMMUNE RESPONSES IMPLEMENTING A VACCINATION NODE
US20060264380A1 (en) 2003-07-21 2006-11-23 Mats Hellstrom Compounds and Methods for Promoting Angiogenesis
GB0317999D0 (en) 2003-07-31 2003-09-03 Univ Liege Improvements in or relating to drug delivery systems
CA2533926C (en) 2003-07-31 2013-10-15 Endacea, Inc. Methods and compositions for producing antigenic responses
CA2535857A1 (en) 2003-08-29 2005-03-10 Mayo Foundation For Medical Education And Research Hydrogel porogens for fabricating biodegradable scaffolds
JP5097400B2 (ja) 2003-09-03 2012-12-12 デンドリセラピューティクス、インク. 複合ワクチン
NZ627167A (en) 2003-10-16 2015-10-30 Stephen John Ralph Immunomodulating compositions and uses therefor
JP2007510470A (ja) 2003-11-07 2007-04-26 カーネギー・メロン・ユニバーシテイ 最小侵襲性介入用ロボット
CA2448995A1 (en) * 2003-11-12 2005-05-12 James Keenan Device and method for attracting diseased cells and foreign substances
JP2005160669A (ja) 2003-12-02 2005-06-23 Olympus Corp 生体組織補填体の製造方法
JP2005170816A (ja) 2003-12-09 2005-06-30 Naoki Ishiguro 軟骨修復用材料、およびその製造方法
WO2005072088A2 (en) 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof
US11395865B2 (en) 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US7192693B2 (en) 2004-02-24 2007-03-20 University Of Washington Methods for photopatterning hydrogels
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
JP5367266B2 (ja) 2004-10-12 2013-12-11 エフエムシー バイオポリマー エイエス 自己ゲル化性アルギネート系及びその使用
US7999161B2 (en) 2005-01-22 2011-08-16 Alexander Oraevsky Laser-activated nanothermolysis of cells
AU2006226923B2 (en) 2005-03-23 2011-10-13 Mayo Foundation For Medical Education And Research Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery
WO2006105278A2 (en) 2005-03-29 2006-10-05 The Regents Of The University Of California Controlling stem cell destiny destiny with tunable network
EP1712238A1 (en) 2005-04-11 2006-10-18 Institut Gustave Roussy Anthracyclin induced immunogenic dead or dying cells composition
US20070003595A1 (en) 2005-04-19 2007-01-04 Shaopeng Wang Three dimensional micro-environments and methods of making and using same
KR101205064B1 (ko) 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 암 면역요법을 위한 조성물과 방법
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
ITPI20050071A1 (it) 2005-06-20 2006-12-21 Giuseppe Calvosa Composizione biocompatibile per la sostituzione/rigenerazione di tessuti
US7645742B2 (en) 2005-06-22 2010-01-12 Advocare International, L.P. Composition for enhancing cellular energy
WO2007022188A2 (en) 2005-08-15 2007-02-22 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery A porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
US20070081972A1 (en) 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
US20070116680A1 (en) 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
RU2420569C2 (ru) 2005-11-29 2011-06-10 Актогеникс Нв Индукция толерантности к антигенам через слизистую
KR100687281B1 (ko) 2005-11-30 2007-02-27 한국과학기술연구원 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법
EP2347774B1 (en) 2005-12-13 2017-07-26 The President and Fellows of Harvard College Scaffolds for cell transplantation
EP1806395A1 (en) 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
US20070178159A1 (en) 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
US20100015709A1 (en) 2006-02-10 2010-01-21 Trustees Of The University Of Pennsylvania Regulating Stem Cell Differentiation By Controlling 2D and 3D Matrix Elasticity
US20070190646A1 (en) 2006-02-10 2007-08-16 The Trustees Of The University Of Pennsylvania Regulating stem cell differentiation by controlling matrix elasticity
EP1988938A4 (en) 2006-02-27 2011-09-28 Agency Science Tech & Res HARDENABLE BONE CEMENT
US9456860B2 (en) 2006-03-14 2016-10-04 Kci Licensing, Inc. Bioresorbable foaming tissue dressing
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
US20090297579A1 (en) 2006-06-01 2009-12-03 Massachusetts Institute Of Technology Control of Cells and Cell Multipotentiality in Three Dimensional Matrices
EP2032149A4 (en) 2006-06-13 2010-09-01 Fmc Biopolymer As METHOD AND SYSTEMS FOR THE USE OF BIOPOLYMER-BASED BEADS AND HYDROGELS
US20070298067A1 (en) 2006-06-22 2007-12-27 Boston Scientific Scimed, Inc. Control release drug coating for medical devices
EP2041175A4 (en) 2006-06-23 2011-03-16 Augmenta Biolog Llc TARGETED IMMUNOJUGATE
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
KR100802139B1 (ko) * 2006-08-08 2008-02-11 한국생명공학연구원 자성 나노입자를 함유하는 골드 나노케이지
KR100818708B1 (ko) 2006-08-18 2008-04-01 주식회사 하이닉스반도체 표면 세정을 포함하는 반도체소자 제조방법
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
GB2455041B (en) 2006-09-21 2012-03-07 Purdue Research Foundation Collagen preparation and method of isolation
CN101534762B (zh) 2006-11-09 2012-09-05 凯希特许有限公司 适合伤口的多孔生物可吸收敷料及其制备方法
WO2008086486A1 (en) 2007-01-10 2008-07-17 The Regents Of The University Of Michigan Porous objects having immobilized encapsulated biomolecules
JP5650406B2 (ja) 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
CA2684578A1 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
WO2008118392A2 (en) 2007-03-22 2008-10-02 The Regents Of The University Of California Synthetic cell platforms and methods of use thereof
CA2699190A1 (en) 2007-04-19 2009-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
AU2008258646A1 (en) 2007-06-05 2008-12-11 Fondazione Centro San Raffaele Del Monte Tabor Induction of tolerogenic phenotype in mature dendritic cells
JP2010531138A (ja) 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性t細胞ならびに同製造および使用方法
WO2009002401A2 (en) * 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
DK2173859T3 (en) 2007-06-29 2016-08-22 Makoto Funaki Soft-gel systems for the modulation of stem cell development
CA2695385A1 (en) 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US20090192079A1 (en) 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
EP2072617A1 (en) 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
WO2011063336A2 (en) 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US20090238853A1 (en) 2008-03-21 2009-09-24 3D Biotek, Llc Hybrid Biomedical Device Fabricated From Biomaterials and Coated With a Natural Extra Cellular Matrix (ECM) Coating
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US20110182957A1 (en) 2008-06-19 2011-07-28 Nicoll Steven B Cellulosics for tissue replacement
US8889124B2 (en) 2008-09-25 2014-11-18 The Board Of Trustees Of The Leland Stanford Junior University Tolerogenic populations of dendritic cells
US8940331B2 (en) 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
KR101132732B1 (ko) 2008-11-26 2012-04-06 한국과학기술연구원 인 시튜 조직재생용 지능형 다공성 생분해 고분자 지지체 및 이의 제조방법
US8273373B2 (en) 2008-12-30 2012-09-25 Case Western Reserve University Photocrosslinked biodegradable hydrogel
JP2010227012A (ja) * 2009-03-27 2010-10-14 Seiko Epson Corp がん細胞捕捉デバイス
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8551749B2 (en) 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
WO2011014871A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
CN101655611B (zh) 2009-09-11 2011-06-08 中国科学院长春应用化学研究所 一种具有双层杂化结构的反蛋白石水凝胶光子晶体的制备方法
CN102656119B (zh) 2009-12-18 2015-11-25 花王株式会社 介孔二氧化硅颗粒的制造方法
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
RU2012143739A (ru) 2010-03-15 2014-04-20 Ферросан Медикал Дивайсиз А/С Способ ускорения остановки кровотечения и/или заживления ран
US20110300186A1 (en) 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
EA023397B1 (ru) 2010-05-26 2016-05-31 Селекта Байосайенсиз, Инк. Комбинированные вакцины с синтетическими наноносителями
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
CN103118678A (zh) 2010-07-16 2013-05-22 约翰斯·霍普金斯大学 用于癌症免疫治疗的方法和组合物
AU2011285639B2 (en) * 2010-08-04 2014-12-18 Georgia Tech Research Corporation Devices, systems, and methods for excavating cancer cells
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
AU2012272937B2 (en) 2011-06-24 2016-09-29 Arqule, Inc Substituted imidazopyridinyl-aminopyridine compounds
CN109125718A (zh) 2012-01-13 2019-01-04 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
EP2838515B1 (en) 2012-04-16 2019-11-20 President and Fellows of Harvard College Mesoporous silica compositions for modulating immune responses
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
WO2016161372A1 (en) 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells

Similar Documents

Publication Publication Date Title
JP2014518893A5 (ja)
JP2017071638A5 (ja)
Chen et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
JP6662381B2 (ja) 立体造形物の製造方法
Sviridov et al. Porous silicon nanoparticles as sensitizers for ultrasonic hyperthermia
JP6843766B2 (ja) 中性子捕捉療法用ビーム整形アセンブリ
Xiang et al. X‐ray acoustic computed tomography with pulsed x‐ray beam from a medical linear accelerator
JP6561171B2 (ja) ナノ銀粒子担持方法
Liu et al. Recent progress in rapid sintering of nanosilver for electronics applications
JP2015536950A5 (ja)
Józefczak et al. Magnetic nanoparticles for enhancing the effectiveness of ultrasonic hyperthermia
JP2016521235A5 (ja)
RU2009145703A (ru) Способ получения светоизлучающих наночастиц алмаза
JP6524391B2 (ja) フッ化マグネシウム焼結体の製造方法、及び中性子モデレータの製造方法
ATE525908T1 (de) Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
JP2014520836A5 (ja)
JP6748110B2 (ja) エネルギーデグレーダ、及びそれを備えた荷電粒子線照射システム
Qasim et al. Effect of off‐axis concentrated loading on failure of curved brittle layer structures
Sun et al. A New Sono‐Chemo Sensitizer Overcoming Tumor Hypoxia for Augmented Sono/Chemo‐Dynamic Therapy and Robust Immune‐Activating Response
JP6806088B2 (ja) 粉末材料、立体造形物の製造方法および立体造形装置
CN105833265B (zh) 新型片层二硫化钼基纳米免疫佐剂及其制备方法与应用
CN208754585U (zh) 一种光子多能量辐照加工能量舱
Goto et al. Electrodeposition of copper/carbonous nanomaterial composite coatings for heat-dissipation materials
Rabiee et al. Effect of CO2 laser power intensity on the surface morphology and friction behavior of alumina ceramic brackets
Jin et al. Experimental and simulation studies on focused ultrasound triggered drug delivery